<code id='CB40057236'></code><style id='CB40057236'></style>
    • <acronym id='CB40057236'></acronym>
      <center id='CB40057236'><center id='CB40057236'><tfoot id='CB40057236'></tfoot></center><abbr id='CB40057236'><dir id='CB40057236'><tfoot id='CB40057236'></tfoot><noframes id='CB40057236'>

    • <optgroup id='CB40057236'><strike id='CB40057236'><sup id='CB40057236'></sup></strike><code id='CB40057236'></code></optgroup>
        1. <b id='CB40057236'><label id='CB40057236'><select id='CB40057236'><dt id='CB40057236'><span id='CB40057236'></span></dt></select></label></b><u id='CB40057236'></u>
          <i id='CB40057236'><strike id='CB40057236'><tt id='CB40057236'><pre id='CB40057236'></pre></tt></strike></i>

          Home / fashion / entertainment

          entertainment


          entertainment

          author:comprehensive    Page View:21
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In